Whole-exome sequencing

YM Yoshiro Morimoto
MS Mihoko Shimada-Sugimoto
TO Takeshi Otowa
SY Shintaro Yoshida
AK Akira Kinoshita
HM Hiroyuki Mishima
NY Naohiro Yamaguchi
TM Takatoshi Mori
AI Akira Imamura
HO Hiroki Ozawa
NK Naohiro Kurotaki
CZ Christiane Ziegler
KD Katharina Domschke
JD Jürgen Deckert
TU Tadashi Umekage
MT Mamoru Tochigi
HK Hisanobu Kaiya
YO Yuji Okazaki
KT Katsushi Tokunaga
TS Tsukasa Sasaki
KY Koh-ichiro Yoshiura
SO Shinji Ono
ask Ask a question
Favorite

We assessed DNA quality using NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA) and Qbit Fluorometer Nucleic Acid Quantification (QIAGEN, Hilden, Germany) and selected four high-quality DNA samples (I-2, I-12, II-10, and II-12) for WES. We performed WES on two affected individuals with PD and two unaffected individuals in this family (Fig. (Fig.1),1), using Agilent SureSelect Exome Target Enrichment System v5 (Agilent Technologies, Santa Clara, CA, USA), followed by paired-end sequencing on SOLiD 5500xl sequencers (Life Technologies, Carlsbad, CA, USA). Mean depth and coverage rate of all samples are summarized in Supplementary Table 3.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A